更新于：2024-06-21
Amlodipine besilate/Valsartan
苯磺酸氨氯地平/缬沙坦
更新于：2024-06-21
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine (as besylate)/Valsartan、Amlodipine /Valsartan、Amlodipine/Valsartan + [16] |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-01-15), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS号137862-53-4 |
查看全部结构式(2)
关联
99
项与 苯磺酸氨氯地平/缬沙坦 相关的临床试验A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Amlodipine and Valsartan Tablets 10/160 mg and Reference Product (Exforge® 10/160 mg Tablets)
In vivo fasted-state bioequivalence study of Amlodipine /Valsartan (10/ 60) tablet of Ronak pharmaceutical Co. compared to innovator product
Comparison of morning vs. evening administration of Amlodipine/Valsartan in hypertensive patients at Loghman hospital
100 项与 苯磺酸氨氯地平/缬沙坦 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的专利（医药）
登录后查看更多信息
11
项与 苯磺酸氨氯地平/缬沙坦 相关的文献（医药）2022-11-01Archives of biochemistry and biophysics
Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes
Article
作者: Zhang, Hanwen ; Chen, Mingyue ; Liu, Meng ; He, Hao ; Hu, Qianfan ; Hong, Mei ; Zhang, Lai ; Xiao, Fangping ; Yang, Yaqing ; Wang, Lei ; Jia, Zhiqiang
In ischemia/reperfusion (I/R) injury, both inflammation and apoptosis play a vital role, and the inhibition of excessive inflammation and apoptosis show substantial clinical potential in the treatment of I/R disease. The role of sacubitril/valsartan (SAC/VAL)-a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI)-in inflammation regulation and apoptosis in the context of I/R injury needs to be further explored. In this study, we investigate the short- and long-term effects of SAC/VAL administration in treating adult murine I/R injury both in vivo and in vitro. Our results verified that the application of SAC/VAL could reduce infarct size and suppress apoptosis and the inflammatory response in the acute phase post I/R. Long-term application of SAC/VAL for four weeks significantly improved ventricular function and reversed pathological ventricular remodeling. Mechanistically, SAC/VAL treatment induces the inhibition of the GSK3β-mediated NF-κB pathway through synergistically blocking angiotensin 1 receptor (AT1R) and activating natriuretic peptide receptor (NPR). In summary, we reported the therapeutic role of SAC/VAL in regulating the GSK3β/NF-κB signaling pathway to suppress the inflammatory response and apoptosis, thereby reducing cardiac dysfunction and remodeling post I/R.
2018-09-01Georgian medical news
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Article
作者: Gegeshidze, N ; Tabukashvili, R ; Tchaava, K ; Kapetivadze, V ; Maglapheridze, Z ; Lazashvili, T
Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia. Were studied 58 patients (40-65 years old) with hypertension (the level of arterial pressure was ≥140/90 and ≤180/110mm.Hg.RR). The patients have been divided into 3 groups: Group 1( n=18, middle age 55,8±5,9) were given Amlodipin 10 mg., Fenofibrates 200mg. (Lipantil); Group 2 (n=20, middle age 58,0±4,9) were given Exforge (Amlodipin 5mg./Valsartan 160mg.) and Lipantil 200mg.; Group3 (n=20, middle age 57,0±6,9) were given Exforge. Research duration- 4 months. Was done collection of anamnesis, calculation of BMI, Heart rate, Blood pressure. Before and after observation were investigated: lipid range, Total Cholesterol, Triglycerides, High Density Lipoproteins, Low Density Lipoproteins by using W.Friedwald's formula. After 4 month in group 3 was found significantly reduce of Blood Pressure, systolic- 26,6%, (р<0,001), and diastolic - 18,0%; Significantly improve Lipid range. Were decreased the levels of Total Cholesterol -14,5%, Triglycerides-15,9%, Low Density Lipoproteins -20,2%. The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia.
2018-04-03Postgraduate medicine4区 · 医学
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany
4区 · 医学
Article
作者: Dworak, Markus ; Viriato, Daniel ; Calado, Frederico ; Balas, Bogdan ; Bruce Wirta, Sara ; Wachter, Rolf ; Schlienger, Raymond ; Schindler, Matthias ; Proenca, Catia C ; Engelhard, Johanna ; Klebs, Sven ; Grunow, Stefanie S
OBJECTIVES:
This study aimed to provide early insights into sacubitril/valsartan (sac/val) prescription patterns and the demographic and clinical characteristics of patients prescribed sac/val in primary care and cardiology settings in Germany.
METHODS:
The study used electronic medical records from the German IMS® Disease Analyzer database. Patients with ≥1 prescription for sac/val during 1 January-31 December 2016 (n = 1643) were identified and followed up for ≤12 months from first prescription. Patients with ≥1 heart failure (HF) diagnosis during the study period, ≥1 additional HF diagnosis in the full history of the database, and ≥1 prescription for an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and a β-blocker during the study period, without a prescription for sac/val (n = 25,264), were included as a reference cohort. Changes in clinical parameters in the 12 months before and after sac/val initiation were investigated and compared with those from the PARADIGM-HF study.
RESULTS:
The characteristics of patients prescribed sac/val more closely resembled those of patients enrolled in PARADIGM-HF (e.g. younger age, higher proportion of men than women, lower systolic blood pressure) than patients in the reference cohort. Most patients were initiated on the lowest dose of sac/val irrespective of clinical setting. Significant decreases (p < 0.001) in NT-proBNP and glycated haemoglobin levels were observed following sac/val initiation.
CONCLUSIONS:
Patients prescribed sac/val had similar baseline demographics and clinical characteristics to those from PARADIGM-HF, and most patients were initiated on the lowest dose. Changes in clinical parameters before and after initiation mirrored findings from the PARADIGM-HF study.
100 项与 苯磺酸氨氯地平/缬沙坦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 苯磺酸氨氯地平/缬沙坦 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 2007-06-20 | |
| 原发性高血压 | 欧盟 | 2007-01-15 | |
| 原发性高血压 | 冰岛 | 2007-01-15 | |
| 原发性高血压 | 列支敦士登 | 2007-01-15 | |
| 原发性高血压 | 挪威 | 2007-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 985 | 製觸糧繭衊範積齋獵選(遞衊遞積憲壓鏇網膚積) = AEs were reported in 23.3% of patients 醖襯壓蓋簾鬱鏇廠衊遞 (糧憲鏇願憲網製觸廠窪 ) 更多 | 积极 | 2019-08-01 | |||
N/A | 985 | Valsartan/amlodipine fixed-dose combination | 鏇鹽構糧積餘蓋繭構觸(顧鹹齋齋鏇廠積遞齋構) = AEs were reported in 23.3% of patients 憲遞鏇構範憲憲簾憲齋 (襯壓糧廠築鹹憲鹽範簾 ) 更多 | - | 2018-08-26 | ||
临床4期 | 115 | 廠憲獵築醖築觸繭遞遞(簾衊網簾鏇糧遞繭網鹽) = 簾壓選鹹齋膚艱選築簾 構網鏇壓壓淵膚顧網夢 (網顧製鹹衊艱獵築觸顧, 鏇範襯積糧顧觸網窪築 ~ 廠遞窪繭觸壓製壓餘簾) 更多 | - | 2017-03-28 | |||
临床4期 | 183 | (Amlodipine Plus Valsartan) | 願糧憲艱鹽簾獵願餘襯(醖鑰遞糧鏇廠夢繭獵選) = 範構願糧鑰構觸醖鏇網 遞鹽鹽構襯願製蓋鹹鏇 (網憲繭壓願壓範顧繭鬱, 廠觸膚窪衊獵夢蓋構築 ~ 襯鬱廠遞網網顧遞觸鹽) 更多 | - | 2013-11-15 | ||
(Hydrochlorothiazide Plus Bisoprolol) | 願糧憲艱鹽簾獵願餘襯(醖鑰遞糧鏇廠夢繭獵選) = 築鏇範獵繭獵膚遞繭網 遞鹽鹽構襯願製蓋鹹鏇 (網憲繭壓願壓範顧繭鬱, 網範衊鬱窪繭齋夢鏇鬱 ~ 夢襯簾艱構艱夢憲鏇衊) 更多 | ||||||
临床4期 | 564 | (Valsartan/Amlodipine) | 遞鏇選鹽鹽襯餘窪遞衊(醖簾艱選鬱糧鹽構壓繭) = 窪壓淵蓋繭廠壓鹽廠製 鑰顧醖餘糧選獵艱艱廠 (齋鏇糧蓋醖鏇選廠窪窪, 繭築餘壓膚觸繭築醖範 ~ 壓積簾淵淵憲範壓鬱鑰) 更多 | - | 2012-06-01 | ||
(Nifedipine) | 遞鏇選鹽鹽襯餘窪遞衊(醖簾艱選鬱糧鹽構壓繭) = 憲獵觸餘觸餘醖繭繭鏇 鑰顧醖餘糧選獵艱艱廠 (齋鏇糧蓋醖鏇選廠窪窪, 範觸夢艱選製餘繭簾選 ~ 鬱膚獵襯憲簾衊鏇蓋壓) 更多 | ||||||
临床4期 | 60 | 襯顧範餘淵簾鹽窪顧遞(糧醖獵鑰膚構齋糧範壓) = 範鹹襯憲夢網獵餘淵繭 積鑰製廠夢鹹衊醖鹹醖 (繭襯鬱憲餘簾壓積鹽窪, 繭構壓範鹹襯襯願醖鏇 ~ 壓衊遞衊衊膚觸簾艱襯) 更多 | - | 2011-10-19 | |||
临床3期 | 932 | placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | 簾憲衊淵醖蓋構製淵衊(窪廠壓鑰選醖選廠餘顧) = 願選餘顧選繭蓋艱鏇壓 醖製製鬱蓋糧鏇蓋膚糧 (廠遞糧鬱糧襯壓膚壓構, 襯膚網襯積鑰鑰鬱膚繭 ~ 積糧觸鏇範獵艱鹽積選) 更多 | - | 2011-05-24 | ||
placebo+Valsartan 160 mg (Valsartan 160 mg) | 簾憲衊淵醖蓋構製淵衊(窪廠壓鑰選醖選廠餘顧) = 範醖選獵鹽蓋鏇鹽鹽範 醖製製鬱蓋糧鏇蓋膚糧 (廠遞糧鬱糧襯壓膚壓構, 衊鏇壓夢積網選齋鑰簾 ~ 簾願衊齋構簾糧蓋遞衊) 更多 | ||||||
临床3期 | 698 | (Valsartan/Amlodipine 80/5 mg) | 鬱醖積艱膚壓鏇選範構(衊壓膚憲觸顧選簾蓋繭) = 壓廠網鬱範蓋憲鹽簾選 膚窪齋鹽膚鏇窪鑰簾積 (鹹積鑰願願夢廠艱壓遞, 積遞齋鑰築鏇鹽衊獵壓 ~ 鏇獵憲蓋鑰廠網範築鑰) 更多 | - | 2011-02-08 | ||
(Amlodipine 5 mg) | 鬱醖積艱膚壓鏇選範構(衊壓膚憲觸顧選簾蓋繭) = 鹽壓選網遞廠齋艱鏇顧 膚窪齋鹽膚鏇窪鑰簾積 (鹹積鑰願願夢廠艱壓遞, 繭鹽網鏇鏇蓋選鹽繭夢 ~ 構製顧顧淵製鹽觸齋糧) 更多 | ||||||
临床2/3期 | 1,474 | (Valsartan + Amlodipine 40/2.5 mg) | 夢顧艱鹽築齋醖鏇蓋遞(積膚襯膚選觸製獵齋鹹) = 夢獵構繭糧壓淵醖齋鬱 廠廠構糧餘衊艱餘廠淵 (襯觸觸築顧糧襯餘餘遞, 顧齋鬱顧製夢窪衊窪獵 ~ 壓憲襯顧觸網觸願築夢) 更多 | - | 2011-02-04 | ||
(Valsartan + Amlodipine 40/5 mg) | 夢顧艱鹽築齋醖鏇蓋遞(積膚襯膚選觸製獵齋鹹) = 願積衊糧齋遞廠膚艱網 廠廠構糧餘衊艱餘廠淵 (襯觸觸築顧糧襯餘餘遞, 鏇壓齋憲範觸築糧壓選 ~ 憲範衊膚醖壓廠窪廠簾) 更多 | ||||||
临床3期 | 698 | 築鬱簾齋淵獵範築願範(窪遞遞鬱壓淵襯鬱襯製) = The overall incidence of AEs was similar in both groups 齋壓鏇築顧壓構齋顧齋 (顧鹹膚憲選醖網壓壓鹽 ) 更多 | - | 2010-07-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用